The landscape of metabolic peptide research has evolved rapidly from single-receptor targets to complex multi-agonist compounds. While semaglutide and tirzepatide have dominated clinical discussions in recent years, retatrutide has emerged in 2026 as a revolutionary subject of investigation. As a “triple-agonist” peptide, retatrutide targets three distinct hormone pathways simultaneously, demonstrating unprecedented metabolic effects in clinical […]
